Opinion|Videos|August 7, 2024
Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy
A key opinion leader examines the November 2022 guidelines for managing Friedreich's ataxia, discusses the first FDA-approved therapy for the condition, and explains how this treatment is integrated into current disease management strategies.
Advertisement
Episodes in this series
- What are some of the key recommendations outlined in the guidelines for managing FA published in November 2022?
- Could you elaborate on the significance of omaveloxolone as the first FDA-approved therapy for Friedreich’s ataxia and how you incorporate this treatment into your disease management regimen? Since the approval of omaveloxolone, what has been the impact on the management of advanced stages of the disease and life expectancy in FA patients?
Advertisement
Related to this article
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
3
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
4
J&J Oncology Care Index Finds Community Innovation Adoption Gap
5